Skip to main content

Advertisement

Table 6 Comparison between the switch and pirfenidone-naïve groups

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

  Switch-group (n = 30) Pirfenidone-naïve group (n = 64) p value
Just before initiation of pirfenidone Just before initiation of nintedanib
Characteristics
 Age 71.0 [67.0, 75.0] 72.0 [68.0, 74.8] 72.0 [65.8, 75.3] 0.903*
 Gender (male/female) 24 / 6 24 / 6 53 / 11 0.778*
 Physique
  Height (cm) 165 [158, 169] 165 [158, 169] 164 [160, 170] 0.958*
  Body weight (kg) 61.4 [59.2, 66.0] 54.9 [49.7, 64.4] 63.2 [54.2, 73.1] 0.01*
  Body mass index 22.6 [21.0, 24.9] 21.0 [19.0, 23.6] 23.9 [20.7, 26.2] 0.001*
  Body surface area (DuBois, m2) 1.69 [1.62, 1.76] 1.59 [1.48, 1.72] 1.68 [1.54, 1.82] 0.063*
 Lung function test
  Forced vital capacity (L) 2.36 [1.78, 3.52] 1.68 [1.34, 1.99] 2.21 [1.74, 2.66] 0.001*
  % Forced vital capacity (%) 62.5 [51.0, 76.6] 52.9 [43.7, 69.7] 67.7 [55.9, 79.0] 0.001*
  % DLco (%) 58.4 [46.7, 65.7] 44.2 [40.9, 58.5] 54.8 [47.6, 67.9] 0.009*
Nintedanib
 Administration period (month) 5.30 [2.84, 11.8] 6.13 [3.02, 14.5] 0.415
 Discontinue within 6 months 16 (53.3%) 21 (32.8%) 0.072
 Adverse events
  AST/ALT elevation 19 (63.3%) 46 (71.9%) 0.475
  Diarrhea 14 (46.7%) 34 (53.1%) 0.659
  Anorexia 14 (46.7%) 14 (21.9%) 0.028
  Weight loss 6 (20.0%) 6 (9.3%) 0.188
  Nausea 2 (6.7%) 11 (17.1%) 0.213
  Fatigue 3 (10.0%) 5 (7.8%) 0.707
  1. Categorical data are presented as numbers (percentages), whereas continuous data are presented as medians (interquartile ranges). *p values were calculated by comparing the baseline characteristics of the switch-group just before nintedanib initiation and the baseline characteristics of the pirfenidone-naïve group. Fisher’s exact test was used to compare categorical data, and the Mann–Whitney U test was used to compare continuous data
  2. Abbreviations: DLCO diffusing capacity for lung carbon monoxide, AST aspartate aminotransferase, ALT alanine aminotransferase